Abstract:Pinyi Zhang, 1 Jianlong Bu, 2 Xiaohong Wu, 1 Lin Deng, 1 Meng Chi, 1 Chao Ma, 3 Xiaoding Shi, 1 Guonian Wang 3 1 Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 2 Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 3 Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Harbin, People's Republic of China Correspondence: Guonian Wang Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Nangang District, Harbin 150081, People's Republic of China Tel +86 15804616023 Email wangguonian609cn@aliyun.com Background: Sustained morphine treatment for cancer pain has been limited due to analgesic tolerance. Opioid receptor internalization and desensitization mediated by downregulation of mu-opioid receptor (MOR) expression have been confirmed as one of the mechanisms of chronic morphine tolerance. In addition to the opiate system, the α 2-adrenergic system is involved in the development of morphine tolerance. Several studies reported that co-administration of α 2-adrenoceptor agonist dexmedetomidine inhibits morphine tolerance in normal or neuropathic pain animals. However, the effect of dexmedetomidine on morphine tolerance has not been studied in cancer pain. Therefore, we investigated the effect of intrathecal injection of dexmedetomidine on the development of morphine tolerance in cancer pain and on the expression of MOR in the spinal cord of morphine-tolerant cancer pain rats. Methods: The model was established using a rat's right hind paw injection of Walker 256 cancer cells. Subcutaneous morphine (10mg/kg) was administrated twice daily for 7 days; meanwhile, the rats received intrathecal α 2-adrenoceptor agonist dexmedetomidine (10μ/kg) or antagonist MK-467 (0.25mg/kg) in test groups. Rats receiving drug vehicle served as the control group. Antinociception was detected by von Frey filaments and hot-plate tests. The expression of MOR in the spinal cord was examined through real-time reverse transcription polymerase chain reaction and Western blotting. The data were analyzed via analysis of variance followed by Student t -test with Bonferroni correction. Results: Seven-day chronic morphine administration elicited notable analgesic tolerance in the rats with cancer pain. Co-administration of α 2-adrenoceptor agonist dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance, which could be blocked by α 2-adrenoceptor antagonist MK-467. Furthermore, pre-treatment of dexmedetomidine significantly upregulated MOR protein expression without a notable change in MOR mRNA expression in the spinal cord. Conclusion: Our findings suggest that intrathecal injection of dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance in cancer pain, potentially by upregulating MOR expression in the spinal cord. The α 2-adrenoceptor agonist may provide a more versatile analgesia option for morphine treatment for cancer pain. Keywords: μ-opioid receptor, MOR, α 2-adrenoceptor, α 2-AR, dexmedetomidine, DEX, morphine tolerance, cancer pain

Repeated Endomorphin Analogue MEL-0614 Reduces Tolerance and Improves Chronic Postoperative Pain without Modulating the P2X7R Signaling Pathway

Endomorphin Analog Exhibited Superiority in Alleviating Neuropathic Hyperalgesia Via Weak Activation of NMDA Receptors.

Peripheral Administration of an Opioid Peptide Analog Ameliorates Morphine-Produced Hyperalgesia in a Spared Nerve Injury Model

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

MEL Endomorphins Act As Potent Inflammatory Analgesics with the Inhibition of Activated Non-Neuronal Cells and Modulation of Pro-Inflammatory Cytokines

Endomorphin-1 Analogues (mels) Penetrate the Blood–brain Barrier and Exhibit Good Analgesic Effects with Minimal Side Effects

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

Melatonin alleviates morphine analgesic tolerance in mice by decreasing NLRP3 inflammasome activation

An opioid peptide analog relieves inflammatory allodynia by the direct inhibition of microglial activation: a μ opioid receptor independent effect

Effect of Metabotropic Glutamate 5 Receptor Antagonists on Morphine Efficacy and Tolerance in Rats with Neuropathic Pain.

Direct inhibition of microglial activation by a μ receptor selective agonist alleviates inflammatory-induced pain hypersensitivity

Comparison of Morphine and Endomorphin Analog ZH853 for Tolerance and Immunomodulation in a Rat Model of Neuropathic Pain

Novel Endomorphin Analogues CEMR-1 and CEMR-2 Produce Potent and Long-Lasting Antinociception with a Favourable Side Effect Profile at the Spinal Level

Melatonin reverses morphine tolerance by inhibiting microglia activation and HSP27 expression

Intrathecal PLCβ3 oligodeoxynucleotides antisense potentiates acute morphine efficacy and attenuates chronic morphine tolerance

Evaluation of Side Effects Through Selective Ablation of the Mu Opioid Receptor Expressing Descending Nociceptive Facilitatory Neurons in the Rostral Ventromedial Medulla with Dermorphin-Saporin.

Novel endomorphin analogs CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favorable side effect profile at the spinal level

Mesenchymal Stem Cells Reversed Morphine Tolerance and Opioid-induced Hyperalgesia

Upregulation of μ-Opioid Receptor in the Rat Spinal Cord Contributes to the α2-Adrenoceptor Agonist Dexmedetomidine-Induced Attenuation of Chronic Morphine Tolerance in Cancer Pain

Lidocaine Alleviates Morphine Tolerance Via AMPK-SOCS3-dependent Neuroinflammation Suppression in the Spinal Cord

Role of Mu Opioid Receptor Exon 7 in Analgesic Efficacy of Endomorphin-1 in Rats